IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC Pharma, Inc. (NYSE American:IGC) has won two awards in Phase 1 of the National Institute on Aging's PREPARE Challenge, which aims to accelerate the development of tools for Alzheimer's and related dementias. The company's entry, using the Mexican Health and Aging Study database, won the Disproportionate Impact prize and placed third overall.
IGC is developing AI and deep learning models to predict cognitive decline up to 20 years before symptoms appear, potentially improving patient outcomes and reducing healthcare costs. CEO Ram Mukunda stated that these recognitions underscore IGC's leadership in AI research for Alzheimer's disease prediction and could help address the projected $1 trillion economic burden on the U.S. healthcare system.
IGC Pharma, Inc. (NYSE American: IGC) ha vinto due premi nella Fase 1 della PREPARE Challenge del National Institute on Aging, che mira ad accelerare lo sviluppo di strumenti per l'Alzheimer e le demenze correlate. L'ingresso dell'azienda, che utilizza il database dello Studio sulla Salute e l'Invecchiamento Messicano, ha vinto il premio Impatto Disproporzionato e si è classificato terzo complessivamente.
IGC sta sviluppando modelli di intelligenza artificiale e deep learning per prevedere il declino cognitivo fino a 20 anni prima della comparsa dei sintomi, potenzialmente migliorando i risultati per i pazienti e riducendo i costi sanitari. Il CEO Ram Mukunda ha dichiarato che questi riconoscimenti sottolineano la leadership di IGC nella ricerca sull'IA per la previsione della malattia di Alzheimer e potrebbero aiutare a affrontare il previsto onere economico di 1 trilione di dollari sul sistema sanitario statunitense.
IGC Pharma, Inc. (NYSE American: IGC) ha ganado dos premios en la Fase 1 del PREPARE Challenge del Instituto Nacional sobre el Envejecimiento, que busca acelerar el desarrollo de herramientas para el Alzheimer y las demencias relacionadas. La entrada de la compañía, utilizando la base de datos del Estudio Mexicano de Salud y Envejecimiento, ganó el premio Impacto Desproporcionado y se ubicó en tercer lugar en general.
IGC está desarrollando modelos de inteligencia artificial y aprendizaje profundo para predecir el deterioro cognitivo hasta 20 años antes de que aparezcan los síntomas, lo que podría mejorar los resultados de los pacientes y reducir los costos de atención médica. El CEO Ram Mukunda declaró que estos reconocimientos subrayan el liderazgo de IGC en la investigación de IA para la predicción de la enfermedad de Alzheimer y podrían ayudar a abordar la carga económica proyectada de 1 billón de dólares sobre el sistema de salud de EE. UU.
IGC Pharma, Inc. (NYSE American: IGC)는 노화 연구소의 PREPARE 챌린지 1단계에서 두 개의 상을 수상했습니다. 이 챌린지는 알츠하이머와 관련된 치매를 위한 도구 개발을 가속화하는 것을 목표로 하고 있습니다. 이 회사의 출품작은 멕시코 건강 및 노화 연구 데이터베이스를 사용하여 불균형 영향 상을 수상하고 전체 3위를 차지했습니다.
IGC는 증상이 나타나기 최대 20년 전에 인지 감소를 예측하기 위한 AI 및 딥러닝 모델을 개발하고 있으며, 이로 인해 환자 결과가 개선되고 의료 비용이 절감될 수 있습니다. CEO Ram Mukunda는 이러한 인식이 알츠하이머병 예측을 위한 AI 연구에서 IGC의 리더십을 강조하며, 미국 의료 시스템에 대한 1조 달러의 경제적 부담이라는 예상 부담을 해결하는 데 도움이 될 수 있다고 언급했습니다.
IGC Pharma, Inc. (NYSE American: IGC) a remporté deux prix lors de la phase 1 du défi PREPARE de l'Institut National sur le Vieillissement, qui vise à accélérer le développement d'outils pour la maladie d'Alzheimer et les démences connues. La soumission de l'entreprise, utilisant la base de données de l'étude mexicaine sur la santé et le vieillissement, a remporté le prix de l'impact disproportionné et s'est classée troisième au général.
IGC développe des modèles d'IA et d'apprentissage profond pour prédire le déclin cognitif jusqu'à 20 ans avant l'apparition des symptômes, ce qui pourrait améliorer les résultats pour les patients et réduire les coûts de santé. Le PDG Ram Mukunda a déclaré que ces reconnaissances soulignent le leadership d'IGC dans la recherche sur l'IA pour la prédiction de la maladie d'Alzheimer et pourraient aider à faire face à la charge économique projetée de 1 trillion de dollars sur le système de santé américain.
IGC Pharma, Inc. (NYSE American: IGC) hat in Phase 1 der PREPARE Challenge des National Institute on Aging zwei Preise gewonnen. Diese Initiative zielt darauf ab, die Entwicklung von Werkzeugen für Alzheimer und verwandte Demenzen zu beschleunigen. Der Beitrag des Unternehmens, der die Datenbank der Mexikanischen Gesundheits- und Alterungsstudie nutzt, gewann den Preis für disproportionale Auswirkungen und erreichte den dritten Platz insgesamt.
IGC entwickelt Künstliche Intelligenz- und Deep-Learning-Modelle, um den kognitiven Abbau bis zu 20 Jahre bevor die Symptome auftreten, vorherzusagen, was potenziell die Patientenergebnisse verbessert und die Gesundheitskosten senkt. CEO Ram Mukunda erklärte, dass diese Auszeichnungen die Führungsposition von IGC in der KI-Forschung zur Vorhersage von Alzheimer-Krankheiten unterstreichen und helfen könnten, die prognostizierte wirtschaftliche Belastung von 1 Billion Dollar für das US-Gesundheitssystem zu adressieren.
- Won Disproportionate Impact prize and placed 3rd overall in NIH's PREPARE Challenge
- Developing AI and deep learning models for early Alzheimer's prediction
- Potential to predict cognitive decline 20 years before symptoms appear
- Aims to reduce the projected $1 trillion economic burden on U.S. healthcare system
- None.
Insights
The recognition of IGC Pharma in the NIH's AI PREPARE Challenge is a positive development, but its immediate impact on the company's financials or market position is likely The awards highlight IGC's progress in AI and deep learning for Alzheimer's prediction, which aligns with a significant unmet medical need.
The potential of IGC's AI initiatives to predict cognitive decline two decades before symptom onset is particularly noteworthy. If successful, this could revolutionize Alzheimer's care and potentially reduce the projected
However, investors should note that this is still early-stage research. The path from AI model development to clinically validated, commercially viable diagnostic tools is long and uncertain. While promising, these awards do not guarantee future market success or regulatory approval.
The company's focus on populations disproportionately impacted by Alzheimer's could provide a competitive edge and address health equity issues, potentially opening doors to specific funding or partnership opportunities.
POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database.
The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institutes of Health ("NIH"). The competition aims to accelerate the development of more accurate, innovative, and representative tools for Alzheimer's and related dementias. The Disproportionate Impact prize recognizes the submission with the most potential to support algorithms that generalize to populations disproportionately impacted by AD/ADRD.
IGC's entry in the Phase 1 of the PREPARE Challenge won the Disproportionate Impact prize, and placed 3rd overall. "We are honored to win the two PREPARE prizes. These recognitions underscore IGC's leadership in artificial intelligence ("AI") and deep learning research aimed at improving Alzheimer's disease prediction," commented CEO Ram Mukunda.
There are approximately 400 million individuals in the preclinical stage of Alzheimer's exhibiting early brain changes, such as plaque buildup, that could lead to cognitive decline within 20 years. By harnessing deep learning models, IGC is developing scalable and cost-effective diagnostic predictors that bypass expensive imaging techniques and ultimately predict cognitive decline two decades before symptoms manifest.
Early prediction improves patient outcomes and can help significantly reduce caregiving and healthcare costs.
Ram Mukunda continued, "We believe our early prediction AI initiatives can offer significant hope to patients and caregivers, create long time value for shareholders, and alleviate the projected
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
Forward-looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on accesswire.com
FAQ
What awards did IGC Pharma win in the NIH's PREPARE Challenge?
How is IGC Pharma (NYSE American:IGC) using AI in Alzheimer's research?
What is the potential impact of IGC Pharma's AI research on Alzheimer's disease?
What database did IGC Pharma (NYSE American:IGC) use for its PREPARE Challenge entry?
